INFECTIOUS DISEASES
Comprehensive disease testing
Through BioPharma Diagnostics, our partners have access to Mayo Clinic Laboratories’ infectious disease test catalog, including testing for:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Helicobacter pylori
- Infectious disease pathology
- Vector-borne diseases
- HIV and hepatitis
Our molecular testing methods include:
- Polymerase chain reaction (PCR) testing
- Advanced whole genome microbial sequencing
- Targeted metagenomic sequencing
- Matrix-assisted laser-desorption/ionization-time of flight (MALDI-TOF) mass spectrometry organism identification
In addition to using clinically available testing, BioPharma Diagnostics partners can access infectious disease testing for clinical trials and be among the first to use up-and-coming tests currently in development.
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.
It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.
In the wake of the CDC withdrawing its emergency use authorization request for a coronavirus PCR test, social media posts claimed the action signaled that the tests were flawed. Dr. Matthew Binnicker explains why those claims are false.
Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory in Mayo Clinic’s Division of Clinical Microbiology, considers the prospects for COVID-19 this fall as the traditional influenza season ramps up.
Elitza Theel, Ph.D., director of Mayo Clinic’s Infectious Disease Serology Lab was featured in a discussion on NBC News about COVID-19 antibody tests.
Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.
When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.
Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.
A small but in-depth study conducted a postmortem evaluation of the heart tissue of 15 patients with COVID-19, including the first postmortem cardiac findings of three patients who had cleared the virus.
Joshua Bornhorst, Ph.D., associate director of Mayo Clinic's Clinical Immunoassay Lab, explains how humans can develop an allergy to the alpha-gal molecule, and he describes a new allergen antibody test that can be used to detect it. Dr. Bornhorst also reviews other tests that should be used in conjunction with alpha-gal testing to accurately identify the scope and underlying cause of the allergy.
Dr. Patel, director of Mayo Clinic's Infectious Diseases Research Laboratory, discussed the future of testing for joint and bone infections.